Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for glycemic control or weight management in patients with type 2 diabetes mellitus or overweight/obesity. However, there are concerns regarding their association with serious gastrointestinal adverse events, although findings have been inconsistent.

Current diagnosis of celiac disease (CeD) is inaccurate in patients consuming a gluten-free diet (GFD). Blood-based diagnostics targeting gluten-specific T cells, such as tetramer assays, are highly sensitive and specific but are impractical for clinical use. We evaluated the potential of a simple, whole-blood assay measuring interleukin 2 (IL2) release (WBAIL-2) for detecting gluten-specific T cells to aid in CeD diagnosis.

Gastrointestinal (GI) clinicians are a critical touchpoint for individuals at risk for genetic and familial syndromes that increase risk of colorectal, gastric and pancreatic cancer. While advances in sequencing technology and reduced costs have made genetic testing more readily accessible to clinicians and even to patients through direct-to-consumer testing, uptake of genetic testing remains underutilized. This is a missed opportunity to identify patients and family members who could benefit from genetic testing to diagnose cancer susceptibility syndromes for which surveillance and preventive interventions exist. Barriers for integration of genetic testing in routine practice include lack of awareness about genetic conditions by patients and providers, concerns about genetic testing costs and implications for insurability, as well as challenges in implementing algorithms for risk assessment and coordinated care in complex medical systems. This review addresses current evidence and guidelines for cancer risk assessment, genetic testing and management to enable GI clinicians to identify and care for individuals with genetic cancer-predisposition syndromes in routine practice.

In a treat-to-target era, objective disease assessment in inflammatory bowel disease has become increasingly important. For many years, endoscopy has been generally accepted as the gold standard for evaluating the bowel mucosa, additionally facilitating biopsy. However, noninvasive disease assessment is now increasingly demanded, and cross-sectional imaging techniques, as well as video capsule endoscopy, have markedly improved. Emerging evidence demonstrates the added clinical value of transmural assessment both in Crohn's disease and ulcerative colitis, and cross-sectional imaging methods are increasingly used in phenotyping and monitoring patients with inflammatory bowel disease. In the current review, we propose potential algorithms to use noninvasive imaging in various clinical scenarios and for use in daily practice. The readers will come away with an understanding of what imaging they should consider for different clinical situations and the strengths and limitations of each method. Future developments of noninvasive diagnostic strategies and areas in need of further research are highlighted.

There is limited data on inflammatory bowel disease advanced therapy sequences. Therefore, we examined real-world advanced therapy sequences to compare persistence, healthcare use and costs in first-line advanced therapy.

ZBTB10 is a member of the zinc finger and bric-a-brac/tramtrack/broad (ZBTB) domain-containing protein family, reported to be associated with tumorigenesis and progression. However, its specific roles in oncogenesis, prognosis, and immune infiltration in stomach adenocarcinoma (STAD) remain to be elucidated.

The prognostic significance of the Platelet-to-Lymphocyte Ratio (PLR) in patients with hepatocellular carcinoma (HCC) undergoing treatment with immune checkpoint inhibitors (ICIs) remains uncertain. A systematic review and meta-analysis was conducted to assess the prognostic value of PLR in HCC patients receiving ICIs.

Monogenic inflammatory bowel disease (mIBD) in patients with onset after the age of 16 has been increasingly recognized, but these reports are sporadic and lack a systematic overview, leaving the clinical and genetic characteristics poorly understood. This study aimed to characterize these late-onset mIBD (LO-mIBD), using an infantile-onset population as a control.

NDC80, a crucial component of the kinetochore, plays a pivotal role in regulating cell mitosis. Recent studies reported that NDC80 regulates the proliferation of cancer cells and may be related to poor prognosis in cancer. However, the biological function and mechanism of NDC80 in esophageal squamous cell carcinoma (ESCC) have not yet been elucidated. In this study, we analyzed the expression and mutation of NDC80 in ESCC tissue and assessed its impact on ESCC cells in vitro.

Small-bowel capsule endoscopy (SBCE) is an essential diagnostic tool for obscure gastrointestinal bleeding, particularly for identifying bleeding sources in the small intestine. The timing of SBCE is thought to affect its diagnostic yield; however, the optimal timing remains unknown.